Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2001

• Venue

  International Journal of Geriatric Psychiatry

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/gps.409PMID 11571763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw

  1999cited by this paper
• Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

  1998cited by this paper
• Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study

  1998cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial

  1996cited by this paper
• Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.

  1996cited by this paper
• Tacrine

  1995cited by this paper
• The Clinician Interview‐ Based Impression (CIBI)

  1994cited by this paper
• Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.

  1994cited by this paper
• Galanthamine treatment in Alzheimer's disease.

  1991cited by this paper
• Measurement of quality-of-life changes in patients with Alzheimer's disease.

  1989cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer’s disease: a nationwide real-world study

  2026cites this paper
• Efficacy of medications in controlling cognitive dysfunction in Alzheimer’s : a systematic review

  2025cites this paper
• Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine

  2025cites this paper
• Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review

  2025cites this paper
• Alkaloids as neuroprotectors: targeting signaling pathways in neurodegenerative diseases

  2025cites this paper
• Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.

  2024cites this paper
• Unveiling of Indanone‐Benzimidazole Hybrids as Anti‐Alzheimer's Agents: Computational and Experimental Studies

  2024cites this paper
• Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia

  2024cites this paper
• Protective effects of L-arginine on Alzheimer's disease: Modulating hippocampal nitric oxide levels and memory deficits in aluminum chloride-induced rat model.

  2023cites this paper
• Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

  2023cites this paper
• The influence of heat stress on the antioxidant protection glutathione link and the content of lipid peroxidation products in chicken liver

  2023cites this paper
• Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

  2023cites this paper
• Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.

  2023cites this paper
• Pyrimidine analogues for the management of neurodegenerative diseases

  2022cites this paper
• Galanthus nivalis L. (snowdrop)

  2021cites this paper
• Genetic Differences in Dorsal Hippocampus Acetylcholinesterase Activity Predict Contextual Fear Learning Across Inbred Mouse Strains

  2021cites this paper
• Pharmacological exploration of traditional plants for the treatment of neurodegenerative disorders

  2020cites this paper
• Cognitive Enhancement and Neuroprotective Abilities of Plants

  2020cites this paper
• Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’s Disease

  2020cites this paper
• Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2020cites this paper
• Efficacy of Ethanolic Extract of Opuntia ficus-indica var. saboten Stems for Improving Cognitive Function in Elderly Subjects 55–85 Years of Age: A Randomized, Double-Blind, Placebo-Controlled Study

  2020cites this paper
• Clinical impact of high-profile animal-based research reported in the UK national press

  2020cites this paper
• Drugs Modulating CD 4 + T Cells Blood-Brain Barrier Interaction in 2 Alzheimer ' s Disease 3

  2020cites this paper
• Treating disorders across the lifespan by modulating cholinergic signaling with galantamine

  2020cites this paper
• Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer’s Disease: A Bayesian Network Meta-Analysis

  2020cites this paper
• Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.

  2020cites this paper
• A Randomized, Double Blind, Vehicle Controlled, Parallel, Phase Ii Study to Evaluate Efficacy and Safety of Bac in Patients With Alzheimer’s Disease or Vascular Dementia

  2020cites this paper
• Galantamine plasma concentration and cognitive response in Alzheimer’s disease

  2019cites this paper
• Therapeutic Agents for Neurodegenerative Disorders

  2019cites this paper
• Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer’s Disease: A Network Meta-Analysis

  2019cites this paper
• Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

  2019cites this paper
• Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease

  2019cites this paper
• The Role of Natural Products in Alzheimer's and Parkinson's Disease

  2018cites this paper
• Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.

  2018cites this paper
• A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia

  2018cites this paper
• Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial

  2018cites this paper
• Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.

  2017cites this paper
• Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis

  2017cites this paper
• Physiological and pathological processes of synaptic plasticity and memory in drug discovery: Do not forget the dose‐response curve

  2017cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

  2017cites this paper
• Association between Anti-Dementia Treatment Persistence and Daily Dosage of the First Prescription: A Retrospective Analysis in Neuropsychiatric Practices in Germany

  2017cites this paper
• Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations

  2016cites this paper
• Alzheimer Disease: Various Therapeutic Interventions and Alternative under Clinical Trial

  2016cites this paper
• Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes.

  2016cites this paper
• Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease

  2016cites this paper
• The role of hypertension and inflammation on the cognitive symptoms of Alzheimer's disease patients

  2016cites this paper
• Design, synthesis, and AChE inhibitory activity of new benzothiazole-piperazines.

  2016cites this paper
• Treatment of Alzheimer's Disease: Classical Therapeutic Approach

  2016cites this paper
• Estimation after subpopulation selection in adaptive seamless trials

  2015cites this paper
• Effect of Low-Intensity Ultrasound on Mortality of PC12 Induced by Amyloid β25–35

  2015cites this paper
• Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial

  2015cites this paper
• Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors

  2015cites this paper
• Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials.

  2015cites this paper
• The Effects of Galantamine Treatment on Attention and Its Relationship with Cognition and Activities of Daily Living in Patients with Mild to Moderate Alzheimer's Disease

  2015cites this paper
• The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer's disease: a Bayesian network meta‐analysis

  2015cites this paper
• Slowing the progression of Alzheimer's disease; what works?

  2015cites this paper
• Efficacy and safety of galantamine treatment for patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials

  2015influential citation
• Effect of Low-Intensity Ultrasound on Mortality of PC12 Induced by Amyloid β25–35

  2015cites this paper
• Child and Adolescent Psychiatry.

  2015cites this paper
• The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial

  2014cites this paper
• Pharmacological Treatment of Cognitive Symptoms in Alzheimer's Disease

  2014cites this paper
• Cognitive Subdomain Responses to Galantamine in Alzheimer’s Disease

  2014cites this paper
• A comparison of methods for constructing confidence intervals after phase II/III clinical trials

  2014influential citation
• Screening for Cognitive Impairment in Older Adults: A Systematic Review for the U.S. Preventive Services Task Force

  2013influential citation
• African Medicinal Plants Acting on the Reproductive, Cardiovascular, and Central Nervous Systems

  2013cites this paper
• A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease

  2013cites this paper
• Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force

  2013cites this paper
• Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease

  2013cites this paper
• Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease

  2012cites this paper
• Gaining precision on the Alzheimer's Disease Assessment Scale‐cognitive: A comparison of item response theory‐based scores and total scores

  2012cites this paper
• A review of the medicinal properties and applications of pycnanthus angolensis (WELW) warb

  2012cites this paper
• The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

  2012cites this paper
• Galantamine

  2012cites this paper
• Group-Sequential Methods for Adaptive Seamless Phase II/III Clinical Trials

  2011cites this paper
• Dementia Medications and Risk of Falls, Syncope, and Related Adverse Events: Meta‐Analysis of Randomized Controlled Trials

  2011cites this paper
• Long-Term Response to Galantamine in Relation to Short-Term Efficacy Data: Pooled Analysis in Patients with Mild to Moderate Alzheimer’s Disease

  2011cites this paper
• Galantamine: an update

  2011cites this paper
• Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.

  2011cites this paper
• Empirical Evidence of Associations Between Trial Quality and Effect Size

  2011cites this paper
• Presynaptic muscarinic receptor subtypes involved in the enhancement of spontaneous GABAergic postsynaptic currents in hippocampal neurons

  2011cites this paper
• Natural Products in the Drug Discovery Programmes in Alzheimer ’ s : Impacts and Prospects

  2011cites this paper
• The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease.

  2011cites this paper
• Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment.

  2011cites this paper
• Long-term Effects of Galantamine Treatment on Brain Functional Activities as Measured by PET in Alzheimer's Disease Patients

  2011cites this paper
• [Guidelines for the medical treatment of patients with Alzheimer's disease].

  2011cites this paper
• Bioactive paper dipstick sensors for acetylcholinesterase inhibitors based on sol-gel/enzyme/gold nanoparticle composites.

  2010cites this paper
• Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

  2010cites this paper
• Efficacy and Safety of Galantamine Hydrobromide in the Treatment of Mild to Moderate Dementia

  2010cites this paper
• M1 and M4 muscarinic acetylcholine receptor regulation of neurotransmission and cell excitability in rodent hippocampus and prefrontal cortex.

  2010cites this paper
• Quantitative Pharmacology Approach in Alzheimer’s Disease: Efficacy Modeling of Early Clinical Data to Predict Clinical Outcome of Tesofensine

  2010cites this paper
• Cholinesterase inhibitors and the risk of pulmonary disorders in hospitalized dementia patients.

  2010cites this paper
• Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer's disease.

  2010cites this paper
• A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information

  2010cites this paper
• Disease progression meta‐analysis model in Alzheimer's disease

  2010cites this paper
• The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease.

  2010cites this paper
• Leitliniensynopse zur S3-Leitlinie »Demenzen« (November 2009)

  2010cites this paper
• Interval estimation for drop-the-losers designs

  2010cites this paper
• Galantamine for Alzheimer's disease

  2010cites this paper
• A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

  2009cites this paper